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HPLCAbstract The method has been developed and validated for the simultaneous determination of
pioglitazone and H1-receptor antagonists (fexofenadine, cetirizine and levocetirizine) in formula-
tions and human serum. Utilizing HPLC techniques, an assay was designed to determine the
in vitro effects of pioglitazone on H1-receptor antagonists. Obtained results were verified using
the UV spectrophotometric technique. First-derivative values versus concentrations were used to
plot calibration curves of these drugs and were found to similar with the HPLC data. The availabil-
ity of pioglitazone remained unchanged in absence or presence of fexofenadine, cetirizine and levo-
cetirizine. This in vitro analysis confirms the harmless co-administration of pioglitazone and H1-
receptor antagonists, and can serve as the foundation for designing further in vivo studies.
 2015 University of Bahrain. Publishing services by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In current days, a close inter-relationship has been identified
between inflammation, insulin resistance and lipid disorders
in diabetic and non-diabetic patients (Haffner et al., 2002).
Thiazolidinediones are peroxisome proliferator-activated
receptor gamma (PPARc) agonists that target insulin resis-
tance directly (Irons et al., 2006; Qayyum and Schulman,
2006). Pioglitazone reduced the risk of the primary endpointand secondary macro-vascular trial in a patient with type 2
diabetes (Erdmann and Wilcox, 2008).
Histamine H1-receptor antagonists are used for the treat-
ment against allergic disorders, particularly rhinitis, conjunc-
tivitis, dermatitis, urticaria and asthma (Chen et al., 2003).
Long term administration of histamine H1-receptor antago-
nists may have a depressing effect on central nervous system
in diabetic patients (Kamei et al., 2005). Moreover, second
generation histamine H1-receptor antagonists cause sedation
by crossing blood brain barrier in diabetic patients (Stauber
et al., 1981).
Controlling blood sugar levels are crucial for diabetics hav-
ing several allergic disorders and depression is more prevalent
in diabetic patients than the general population (Anderson
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receptor antagonists is common. This co-administration
increases the risk for significant drug–drug interactions. In vitro
drug interaction studies of H1-receptor antagonists have also
been reported in the literature (Kenawi et al., 2005a,b), but
these studies contains lacks of physiological conditions and
typically the lack of other confounding physiological processes.
The robust and non classical methods have an important
application in the pharmaceutical industry associated with
drug development and drug interaction processes such that
strong, dependable information can be put into a clinical
framework. These assays must be able to clinically examine
for suitable drug interaction studies. As in combination thera-
pies, co-administration of drugs increases the risk for signifi-
cant drug–drug interactions.
Currently, it is important to ponder drug–drug interactions
using appropriate in vitro/in vivo studies to guide clinical inter-
action studies. The goal of designing a method for in vitro
interaction studies is the prediction of clinical parameters. In
vitro techniques offer a complete means to create a huge
amount of data using minimum resources. Investigation of
in vitro drug interactions has also been reported by using min-
imum standards (Arayne et al., 2008, 2010c,d; Mirza et al.,
2013b; Shamshad et al., 2014). These suggested that in vitro
approaches should be properly characterized; validated and
proper controls should be incorporated in routine use. Of
the available in vitro techniques, dissolution test model offers
several advantages. In pharmaceutical industry, this is
commonly used to conduct formulation design. It is the only
test that measures the rate of in vitro drug release, which can
simulate in vivo drug release (Brown et al., 2004).
The present paper describes the design and validation of
simultaneous methods for the determination of pioglitazone,
fexofenadine, cetirizine or levocetirizine using HPLC tech-
niques, which are robust, convenient and specific, have good
dynamic range, make interpretable results of significance to
clinicians and have reasonable throughput. These are the
co-prescribed and co-administered drugs. The present work
also seeks to assess the actual suitability and general applica-
bility of in vitro methods for interaction of the drugs, pioglita-
zone with fexofenadine, cetirizine and levocetirizine, through
the application of dissolution test, HPLC and UV spectropho-
tometry techniques. An in vitro assay was established to
demonstrate and identify potential drug–drug interaction.
Existing assays carried out to assess the interactions of ceti-
rizine, lacked uniformity of approach and were designed as
such, not fulfilling the information requirements of clinical rel-
evance neither proving of eminence to industries, but for rou-
tine application in drug discovery and development process
(Kenawi et al., 2005a,b). The present study has not been made
previously and therefore it provides a potential explanation for
the observed effect.
Two negative in vitro interactions of H1 receptor antago-
nists (Arayne et al., 2010d; Sultana et al., 2010) and one
in vitro interaction of pioglitazone with losartan have been
reported by UV spectrophotometry and HPLC techniques
(Mirza et al., 2013a).
It is also observed that, there are several simultaneous
HPLC methods reported for the determination of pioglitazone
(Arayne et al., 2010a, 2011; Mirza et al., 2015, 2013a) and H1
receptor antagonists (Arayne et al., 2010b) and a UV
spectrophotometric method of H1 receptor antagonist(Raghu and Basavaiah, 2012) but there no method for the
simultaneous determination of pioglitazone, fexofenadine, cet-
irizine or levocetirizine has been reported by HPLC. The
method was validated for the parameters like linearity, speci-
ficity, accuracy and intermediate precision, limit of detection
and quantitation.
2. Experimental
2.1. Materials
Pioglitazone hydrochloride reference standard were gifted
from PharmEvo (Private) Limited Karachi. Poze (Pioglita-
zone 45 mg) tablets were purchased from a local pharmacy.
The H1-receptor antagonists, fexofenadine, cetirizine and levo-
cetirizine were obtained from various pharmaceutical compa-
nies. Fexet (30 mg), Zyrtec (10 mg) and Xyzal (45 mg)
tablets were purchased from a local pharmacy. HPLC grade
methanol was purchased from Merck, Germany.
2.2. Instrumentation
Double beam UV visible spectrophotometer (Shimadzu UV-
1601) and HPLC, with LC-10 AT VP pump, SPD-10A VP
UV–vis detector utilizing a Purospher STAR RP-18 end
capped (5 lm, 25  0.46 cm) column were used. Shimadzu
Class-GC 10 software (version 2) was used for data acquisi-
tion. JP XIV type 2 apparatus (rotating paddle method, Model
NTR-6100A, Toyama-sangyo, Osaka, Japan) with B.P. 2005
specifications was utilized for dissolution profiles (British
Pharmacopoeia, 1998).
2.3. Chromatographic technique
2.3.1. Preparation of stock solutions
Stock solutions of pioglitazone and H1-receptor antagonists of
100 lg mL1 were prepared in methanol. Twenty tablets of
each drug were weighed and triturated to obtain a homoge-
neous mixture. By dissolving the suitable amount of each pow-
der in methanol, sample solutions at 100 lg mL1
concentration of active substance were prepared.
2.3.2. Chromatographic conditions
Isocratic elution with mobile phase of methanol: water (65:35
v/v), pH of 2.55 adjusted with phosphoric acid with a flow rate
of 1 mL min1 and isosbestic wavelength at 230 nm was used
for the development of the method. Diluents consisted of
methanol: water (70:30 v/v) with analysis performed at room
temperature (24 ± 2 C). Representative chromatogram is
shown in Fig. 1.
3. Method development
3.1. Assessment of linearity and recovery studies
Linearity was assessed by using two sets of five standard and
recovery and matrix effects was observed using solutions at
concentrations of 2.5–25 lg mL1 for pioglitazone and
5–50 lg mL1 for each H1-receptor antagonists in methanol.
The linearity of each standard curves were assessed by plotting
Figure 1 Representative chromatogram of pioglitazone (1),
fexofenadine (2) and levocetirizine (3).
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(Table 1). The mean relative standard deviation (%R.S.D.)
was <2.0% and % recovery was above 99.74% for pioglita-
zone, 99.29% for fexofenadine, 99.01% for cetirizine and
99.60% for levocetirizine (Table 2). In the second set, five stan-
dard lines were constructed using plasma. The plasma samples
were subjected to protein precipitation with methanol prior to
a HPLC analysis. The reported method was used for serum
analysis (Mirza et al., 2015, 2013a). 10 mL blood samples from
ten healthy volunteers were collected and centrifuged at
3000 rpm for 10 min followed by the addition of 1 mL of
methanol for protein precipitation. After centrifugation at
15,000 rcf for 5 min, clear extracts were collected, fortified with
pioglitazone and H1 receptor antagonists solutions and were
injected into the HPLC column (Fig. 2). The recovery was
expressed as the ratio of mean peak area of all drugs spiked
to the mean peak area of the same analyte standards multiplied
by 100 (Table 3).
3.2. Specificity
According to ICH ‘‘specificity is the ability to assess unequiv-
ocally the analyte in the presence of components that may be
expected to be present in the sample matrix” (ICH, 2005). InTable 1 Regression statistics and LOD and LOQ.
Drug Regression equation Slope %RSD
Pioglitazone y= 7741x+ 44036 0.02
Fexofenadine y= 4404x – 12523 0.09
Cetirizine y= 8563x+ 42072 0.09
Levocetirizine y= 8554x+ 42470 0.10
Table 2 Results from recovery studies of pioglitazone, fexofenadin
Levels in spiked
samples
Recovery
%
%
RSD
Levels in spiked
samples
lgmL1 Pioglitazone lg mL1
5 102.4 1.11 10
10 102.1 0.92 20
15 101.4 0.78 30order to determine the specificity of the method in the presence
of pharmacopeial excipients (i.e. microcrystalline cellulose,
croscarmellose sodium, magnesium stearate, lactose and hydro
xypropylmethylcellulose), no peak of excipients was found in
chromatogram, which proved that the method can be applied
successfully to dosage formulation.
3.3. Accuracy and intermediate precision
Three consecutive measurements at three different concentra-
tions of pioglitazone (8, 10 and 12 lg mL1) and H1 receptor
antagonists (16, 20 and 24 lg mL1) were performed for each
concentration within the same day and on 3 different days
(Table 4).
3.4. Limit of detection and quantitation
Limit of detection (LOD) and limit for quantitation (LOQ) of
pioglitazone and H1 receptor antagonists were determined by
the following equations according to ICH guidelines (ICH,
2005).
LOD ¼ 3:3r
S
ð1Þ
LOQ ¼ 10r
S
ð2Þ3.5. Interaction studies
Powder equivalent to 20 mg of crushed tablets of each drug,
was transferred to separate 100 mL volumetric flasks using
buffer solution as diluent. 100 lg mL1 of each drug was
mixed in reaction flasks by taking equal volume of pioglita-
zone and each H1 receptor antagonists. These flasks were
maintained in water bath at 37 C with constant stirring and
2 mL was withdrawn at zero minute and periodically after
every 15 min interval for continuous two hours. Withdrawn
aliquots after dilution with methanol to 10 mL were
chromatographed.r2 LOD lg mL1 LOQ lg mL1
0.9963 0.19 0.66
0.9961 0.71 2.37
0.9958 0.30 1.00
0.9961 0.29 0.95
e, cetirizine and levocetirizine.
Recovery
%
%
RSD
Recovery
%
%
RSD
Recovery
%
%
RSD
Fexofenadine Cetirizine Levocetirizine
97.9 1.01 98.2 1.21 99.5 0.79
99.3 0.98 98.6 0.88 99.4 1.21
99.3 0.91 98.9 0.87 99.2 1.09
Figure 2 Representative chromatogram of pioglitazone (1),
fexofenadine (2) and levocetirizine (3) in human serum.
Table 4 Accuracy and precision.
Analyte Spiked
concentration
(lg mL1)
Precision
%RSD
Accuracy
%
Pioglitazone 8 1.23 98.75
10 1.58 101.07
12 0.66 100.56
Fexofenadine 16 1.61 99.86
20 1.05 99.30
24 0.65 100.76
Cetirizine 16 1.60 99.61
20 1.80 99.66
24 2.59 99.02
Levocetirizine 16 1.65 99.71
20 1.75 99.61
24 2.07 100.09
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Standard stock solution of 35.6 lg mL1 was prepared by tak-
ing 0.0356 g pioglitazone hydrochloride in buffer of pH 1. Cal-
ibration curves for linearity studies were performed between
the concentration of 3.5–35.6 lg mL1 for pioglitazone, 5–
25 lg mL1 for cetirizine, 5–25 lg mL1 for levocetirizine
and 10–50 lg mL1 concentrations for fexofenadine, in simu-
lated gastric juice (buffers of pH 1) (Fig. 3). In vitro availabil-
ities of pioglitazone and H1-receptor antagonists were
performed in individual dosage forms, using 500 mL of simu-
lated gastric juice, which was used as dissolution medium
(Table 5). This dissolution medium was selected on the basis
of availability of pioglitazone (Mirza et al., 2013a).
4.1. Interaction studies
Reported methods were utilized for interaction (Arayne et al.,
2008, 2010c,d; Mirza et al., 2013a; Shamshad et al., 2014).
Briefly, in each set of experiment, pioglitazone tablet was
added into the dissolution medium along with fexofenadine,
cetirizine or levocetirizine tablets at zero minute. Aliquots were
withdrawn periodically from 0 to 120 min, at 15 min intervals,
and assayed and calculations were performed (Table 6).
5. Results and discussion
Simple and reliable simultaneous HPLC method for the deter-
mination of these drugs in active and serum have been devel-
oped for the first time. The method has an advantage of
being simple, rapid and free of any extensive sample prepara-
tion, purification and extraction processes.
In order to comprehensively determine the potential for
clinical drug–drug interactions, number of in vitro drug
interaction models will be required. Reported assays haveTable 3 Results of recovery studies of pioglitazone, fexofenadine, c
Levels in spiked
samples (lg mL1)
Pioglitazone Levels in spiked
samples (lg mL1)
Recov. %RSD
5 4.97 1.11 10
10 9.89 1.63 20
15 15.21 0.28 30deficiency in approach, robust quality standards and were
not designed to provide information of clinical relevance
(Kenawi et al., 2005a,b). The present study provides a consis-
tent and relevant in vitro parameter, which could be used to
identify a potential drug–drug interaction. No significant
change in the availability of pioglitazone was found in the
presence fexofenadine, cetirizine and levocetirizine (Table 7).
No changes in the availability of pioglitazone in the absence
or presence of fexofenadine, cetirizine and levocetirizine were
observed. Similar results were obtained using both techniques
such as HPLC and spectrophotometer.
Beer’s equation was used to quantitate the in vitro availabil-
ity of pioglitazone, fexofenadine, cetirizine and levocetirizine
as shown in Table 6. The absorption maxima of pioglitazone,
fexofenadine, cetirizine and levocetirizine were at 269, 220, 231
and 231 nm, respectively (Fig. 3) and were interfered with each
other. Derivative spectroscopic technique was used to resolve
this problem. This technique presents the solution for the elim-
ination of analytical interference and allows the determination
of one or more wave-lengths, where the compound of interest
can be analyzed with zero absorption from the formulation
matrix (Wang and Asgharnejad, 2000). First derivative values
versus concentration was used to draw calibration curves of
these drugs which were found to be linear over the range.
The absence of any interaction was evident from the similar
availability values as shown in Table 6. The results acquired
were in accordance with the HPLC data. The results of the
HPLC method demonstrate that simultaneous determination
of pioglitazone, fexofenadine, cetirizine or levocetirizine is very
beneficial for pharmaceutical manufacturers and clinicians.
The proposed method is simple and suitable for the analysisetirizine and levocetirizine in human serum.
Fexofenadine Cetirizine Levocetirizine
Recov. %RSD Recov. %RSD Recov. %RSD
10.04 0.84 10.06 0.74 10.06 0.74
20.09 0.62 20.19 0.65 20.12 1.51
30.14 0.98 30.14 0.82 30.25 1.05
Figure 3 Representative spectra of pioglitazone, fexofenadine,
cetirizine and levocetirizine.
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This study thus supports the safe co-administration of piogli-
tazone and H1 receptor blockers as an effective diabetic health
management regimen.Table 5 % Availability of pioglitazone and H1 receptor antagonist
Time (Mins) Pioglitazone % Fexofenadi
0 2 9
15 99 13.4
30 102 13
45 103 12.75
60 103 13.5
75 104 13.05
90 104 12.75
105 104 12.5
120 104 12.95
Table 6 % Availability of pioglitazone, fexofenadine, cetirizine and
Time (Mins) Pioglitazone % Fexofenadine % Pioglitazo
0 0 0 0
15 54.32 0.91 39.32
30 65.38 5.74 45.65
45 96.32 10.58 89.32
60 97.35 10.28 95.32
75 95.32 9.65 96.78
90 98.21 12.36 98.36
105 100.23 13.01 99.98
120 99.23 12.89 99.32
Table 7 % Availability of pioglitazone, fexofenadine, cetirizine and
Time (Mins) Pioglitazone % Fexofenadine % Pioglitazo
0 100.00 100.00 100.00
15 103.13 100.13 98.62
30 102.28 104.04 104.79
45 102.93 102.98 105.02
60 106.35 105.69 105.62
75 107.54 102.87 101.48
90 104.27 104.76 102.39
105 103.22 103.25 102.32
120 102.22 103.22 103.026. Conclusion
The present HPLC method allowed quantitative determination
of pioglitazone, fexofenadine, cetirizine or levocetirizine in for-
mulations and human serum. The proposed method can be
used for routine analysis in quality control laboratories owing
to its application over other methods as it is fast, precise, accu-
rate, sensitive and efficient. The present study also offers a pos-
sibility to a suitable and relevant clinical study to investigate
the interaction. Optimized conditions were used to understand
interaction of pioglitazone on three separate H1 receptor
antagonists with significant reproducibility and robustness.
As a result these methodologies, treatment with fexofenadine,
cetirizine or levocetirizine extensively unchanged the availabil-
ity of pioglitazone compared to its availability alone. It is sug-
gested that receptor or enzymatic level studies should be
carried out to further study the possible interaction by the
combination of these drugs.s in individual dosage forms.
ne % Cetirizine % Levocetirizine %
0 0.89
27.3 100.42
46.69 102.10
65.72 117.58
78.76 115.37
87.76 100.87
94.63 103.59
97.33 113.90
97.51 108.42
levocetirizine after interaction (UV).
ne % Cetirizine % Pioglitazone % Levocetirizine %
0 0 0
35.32 15.32 85.32
40.25 31.25 90.21
72.36 47.92 98.32
78.25 55.32 99.32
85.32 81.29 100.58
90.21 95.32 105.32
95.32 102.32 103.25
95.98 102.10 102.32
levocetirizine after interaction (HPLC).
ne % Cetirizine % Pioglitazone % Levocetirizine %
100.00 100.00 100.00
97.29 105.72 105.21
104.29 107.96 107.74
102.50 102.32 101.15
105.59 102.06 100.89
105.59 104.32 102.91
100.57 103.69 100.37
100.12 100.25 100.26
100.22 102.32 102.00
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